1.Stanaway, JD et al. (2016) The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet 388, 1081–1088.
2.Mokdad, AA et al. (2014) Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. BMC Medicine 12, 145.
3.Global Burden of Disease Cancer Collaboration (2017) Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the Global Burden of Disease Study. JAMA Oncology 3, 524–548.
4.World Health Organization (2017) Global Hepatitis Report 2017. Geneva: World Health Organization.
5.Fattovich, G, Bortolotti, F and Donato, F (2008) Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. Journal of Hepatology 48, 335–352.
6.Chang, TT et al. (2010) Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 52, 886–893.
7.Dienstag, JL et al. (2003) Histological outcome during long-term lamivudine therapy. Gastroenterology 124, 105–117.
8.Ahn, J et al. (2016) Lower observed hepatocellular carcinoma incidence in chronic hepatitis B patients treated with entecavir: results of the ENUMERATE study. American Journal of Gastroenterology 111, 1297–1304.
9.Triolo, M, Della Corte, C and Colombo, M (2014) Impact of HBV therapy on the incidence of hepatocellular carcinoma. Liver International 34(Suppl. 1), 139–145.
10.Riveiro-Barciela, M et al. (2017) Effectiveness and safety of entecavir or tenofovir in a Spanish cohort of chronic hepatitis B patients: validation of the page-B score to predict hepatocellular carcinoma. Digestive Diseases and Sciences 62, 784–793.
11.Hosaka, T et al. (2013) Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 58, 98–107.
12.Iloeje, UH, Yang, HI and Chen, CJ (2012) Natural history of chronic hepatitis B: what exactly has REVEAL revealed? Liver International 32, 1333–1341.
13.Yang, HI et al. (2011) Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncology 12, 568–574.
14.Iloeje, UH et al. (2006) Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 130, 678–686.
15.Lee, MH et al. (2013) Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles. Hepatology 58, 546–554.
16.Chien, J et al. (2016) Risk and predictors of hepatocellular carcinoma for chronic hepatitis B patients with newly developed cirrhosis. Journal of Gastroenterology and Hepatology 31, 1971–1977.
17.European Association for the Study of the Liver (2017) EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. Journal of Hepatology 67, 370–398.
18.Lieveld, FI et al. (2013) Patient adherence to antiviral treatment for chronic hepatitis B and C: a systematic review. Annals of Hepatology 12, 380–391.
19.Beste, LA et al. (2015) Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US veterans, 2001–2013. Gastroenterology 149, 1471–1482, .
20.Fattovich, G et al. (2004) Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 127, S35–S50.
21.Ieluzzi, D et al. (2014) Progression to cirrhosis, hepatocellular carcinoma and liver-related mortality in chronic hepatitis B patients in Italy. Digestive and Liver Disease 46, 427–432.
22.Chen, CJ et al. (2006) Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295, 65–73.
23.Kim, SU et al. (2014) Histological subclassification of cirrhosis can predict recurrence after curative resection of hepatocellular carcinoma. Liver International 34, 1008–1017.
24.Terrault, NA et al. (2016) AASLD guidelines for treatment of chronic hepatitis B. Hepatology 63, 261–283.
25.Liu, J et al. (2014) Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma. Gut 63, 1648–1657.
26.Kim, GA et al. (2014) HBsag seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability. Gut 63, 1325–1332.
27.Lim, TH et al. (2015) Serological and clinical outcomes of horizontally transmitted chronic hepatitis B infection in New Zealand Maori: results from a 28-year follow-up study. Gut 64, 966–972.
28.Yang, H-I et al. (2002) Hepatitis B e antigen and the risk of hepatocellular carcinoma. New England Journal of Medicine 347, 168–174.
29.Cho, JY et al. (2014) Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease. Gut 63, 1943–1950.
30.Zoutendijk, R et al. (2013) Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. Gut 62, 760–765.
31.Sinn, DH et al. (2015) Hepatocellular carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low viral load. Hepatology 62, 694–701.